In solid tumors, neovascularization is a prerequisite for growth. 1, 2) Tumor cells are thought to secrete angiogenic factor(s) that induce neovascularization around the tumors. [3] [4] [5] Vascular endothelial growth factor (VEGF) is a secretable angiogenic factor also known as vascular permeability factor (VPF) or vasculotropin. [6] [7] [8] It specifically promotes the growth of endothelial cells and induces vascular leakage. VEGF protein or its mRNA has been detected in specimens from many cancer patients. [9] [10] [11] [12] [13] [14] [15] [16] [17] VEGF has also been detected in the conditioned medium of many tumor cell lines from different organs, 18) in sera, 19, 20) and in pleural and peritoneal fluid of cancer patients. 21) These findings suggest that VEGF is secreted from a variety of solid tumors in vivo and acts as a tumor angiogenic factor (TAF). We have previously established two neutralizing anti-VEGF monoclonal antibodies (MAbs), MV101 and MV303. These MAbs inhibited the growth of human solid tumor xenografts in nude mice. 22, 23) We therefore tried to develop another neutralizing anti-VEGF MAb with more potent antitumor activity than MV101 or MV303. We obtained more than 140 clones of hybridomas, producing anti-VEGF MAbs, from mice immunized with recombinant human VEGF 121 . Among them, 26 clones showed neutralizing activity and MV833 possessed the most potent antitumor activity in vivo. 24) Here we describe the antitumor activity spectrum of MV833 against 27 human tumors transplanted in nude mice and show that anti-VEGF antibody has the potential to inhibit the growth of many kinds of solid tumors.
MATERIALS AND METHODS
Preparation of an anti-human VEGF MAb, MV833 BALB/c mice (8-week-old, female) were immunized with recombinant human VEGF 121 . 25) Spleen cells were fused with mouse myeloma Sp2/O-Ag14 and hybridomas were cloned by limiting dilution. 24) Hybridoma cells were inoculated i.p. in BALB/c nude mice, and MV833 was purified from ascites fluid using a protein-A column (MAPS-II; Bio-Rad, Cambridge, CA). Cell lines A375, G361, WM-115 (melanoma), LS174T, LS180, HCT116, HT-29, SW480, LoVo (colon carcinoma), PC-3 (prostate carcinoma), PLC/PRF/5 (hapatoma), MIA PaCa-2 (pancreatic carcinoma), A-673 (rhabdomyosarcoma), HT-1080 (fibrosarcoma), and A-431 (epidermoid carcinoma) were supplied by American Type Culture Collection through Dainippon Pharmaceutical Co. (Osaka). Two lung carcinoma cell lines, A549 and PC-14 were purchased from RIKEN Cell Bank (Tsukuba). Two pancreas carcinoma cell lines, BXPC-3 and ASPC-1, were kindly donated by Dr. Toi ) were cultured in 24-well culture plates in 500 µl of D-MEM for 48 h. Amounts of VEGF in the conditioned media were determined by sandwichtype ELISA as described. 19) Angiogenesis induced by tumor cells in vivo In vivo angiogenesis was assayed by the dorsal air-sac method. 22) Briefly, 1×10
7 cultured HT-1080 cells were packed into membrane chambers and implanted into a dorsal air sac of BALB/c mice (day 0). MV833 (100 µg) was administered i.v. from days 1 to 3. The mice were killed on day 4, and Tumor growth in vivo All the human tumors were maintained by serial transplantations in the s.c. region of BALB/c nude mice (Charles River Japan Inc., Kanagawa) housed in specific pathogen-free conditions. Tumors were taken from mice, cut into 2×2×2-mm pieces, and transplanted s.c. into the abdominal region of native nude mice using a trocar. MV833 was administered i.v. through a lateral tail vein every 4 days until the experiments were terminated. The tumor was measured in two dimensions, and volume was calculated using the formula volume= width 2 ×length/2. The control mice were administered the same volume of PBS (phosphate-buffered saline) (0.2 ml/ injection). Table I (Table II) . Inhibition of tumor-induced neovascularization by MV833 Tumor induced neovascularization was examined by implanting HT-1080 cells, packed into membrane chambers, in mice. Neovascularization was evident in the region adjacent to the chamber containing HT-1080 cells after 4 days (Fig. 1) . Three i.v. administrations of MV833 (100 µg) suppressed the neovascularization induced by HT-1080 cells to the level of the control (no tumor cells). These results indicated that MV833 neutralized the activity of VEGF secreted from tumor cells and inhibited tumor-induced neovascularization in vivo. The growth of human VEGF 121 -transformed HeLa cell line and its inhibition by MV833 in vivo The human cervix tumor cell line, HeLa/v5, which was transformed by human VEGF 121 gene, secreted higher levels of VEGF than HeLa/c transformed by control vector, in vitro (Table  I ). The growth of solid tumor of HeLa/v5 s.c. transplanted in nude mice was significantly faster than that of HeLa/c ( Fig. 2; open symbols) . From day 28 to day 70 after the transplantation, the tumor volumes of HeLa/v5 and HeLa/c increased 11.7-and 5.0-fold, respectively. The growth of both HeLa/v5 and HeLa/c tumors was almost completely suppressed by the administration of MV833 ( Fig. 2; closed symbols) . In some tumor lines, treatment with MV833 was delayed until the tumor volume had reached 400-500 mm 3 ; almost complete suppression was observed after the treatment (Fig. 4) .
RESULTS

Secreted VEGF levels and VEGF receptor expression in vitro
Antitumor activity of MV833 against various kinds of human tumors s.c. transplanted in nude mice
DISCUSSION
Neovascularization is necessary for the growth of solid tumors. Solid tumors are thought to secrete TAF, thereby inducing new vessel formation for explosive growth. It is becoming clear that VEGF plays the most important role in tumor angiogenesis among several angiogenic factors so far characterized.
We previously obtained two VEGF-neutralizing monoclonal antibodies, MV101 and MV303, by immunization of mice with human VEGF 121 and established their potential as therapeutic agents for solid tumors. 22, 23) Next, we wished to establish another neutralizing antibody which exhibited higher activity than MV101 and MV303, and we selected MV833 from over 140 clones of hybridomas producing anti-VEGF MAb. 24) In this paper, we deal with the role of VEGF in tumor growth in vivo and the antiangiogenic and antitumor activity of MV833 against various kinds of tumors implanted in nude mice.
I.v. administrations of MV833 to HT-1080 tumor cellimplanted nude mice clearly inhibited tumor cell-induced neovascularization (Fig. 1) . HeLa/v5, 18) which was transfected with human VEGF 121 gene and secreted relatively high levels of VEGF, acquired the ability to grow rapidly in nude mice (Fig. 2) , although its doubling time in vitro was not changed from that of the parental cell line, supporting an important role of VEGF in tumor growth in vivo. The 27 human tumor cell lines originating from various solid tumors, including colon, lung, breast, pancreas, and melanoma, secreted various levels of VEGF into the culture media, though MV833 did not inhibit their growth in vitro (Table I ). The growth of tumors that produced high levels of VEGF (LS180, BXPC-3, A-673, and HT-1080) was relatively fast. MV833 strongly blocked the growth of all kinds of tumors, despite differences in the ability to secrete VEGF in vitro (Tables I and II) . These results again support the idea that VEGF is the most important and generally used TAF among many angiogenic factors.
In some tumors (HT-29, ASPC-1, HRA and PC-14), the inhibition by MV833 was somewhat weak. This could be explained by limited distribution of MV833 in these solid tumors and/or the possible existence of an additional TAF in these tumors, as Kim et al. predicted based on experiments using an anti-VEGF MAb. 26) Two VEGF receptors (Flt-1 and Flk-1/KDR) were expressed specifically on the surface of endothelial cells 27, 28) and only Flk-1/KDR is known as a functional transducer of VEGF's mitogenic signal in endothelial cells. 29) Some tumor cell lines (melanoma, ovarian carcinoma and megakaryoblastic leukemia) were reported to express VEGF receptor, though their growth was not affected by VEGF in vitro. 17, 30, 31) We also observed the expression of VEGF receptors in A375, WM-115 and PC-3 cells (Table I) 35, 36) In this study, we established the strong inhibitory activity of MV833, a neutralizing MAb to human VEGF, against various kinds of solid tumors. The inhibitory spectrum of MV833 was very wide and the degree of inhibition was very large. Moreover, strong inhibition of tumor growth was observed even after delayed administration in some tumor lines tested (Fig. 4) . Unlike cytotoxic antitumor agents, MAb is expected to produce few side-effects and should not induce resistant cells, because it does not work directly on the tumor cells.
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